San Francisco — January 2026 — Massive Bio, a leader in AI-driven clinical trial enrollment and patient access solutions, today announced the launch of Reticulum Nexus™, a next-generation platform designed to fundamentally redefine how patients are identified, engaged, and enrolled in clinical trials. The announcement coincides with the J.P. Morgan Healthcare Conference, where Massive Bio is meeting with investors, biopharma leaders, and strategic partners.
Reticulum Nexus represents a decisive shift away from static patient-matching tools toward a fully autonomous, AI-first operating system for clinical trials. Built on an embedded agentic framework, the platform orchestrates the entire enrollment lifecycle—intelligently coordinating data, decisions, and actions across patients, sites, and sponsors.
“Reticulum Nexus is not an incremental improvement—it is a category-defining platform,” said Selin Kurnaz, PhD, Co-founder and CEO of Massive Bio. “We built this system to move clinical trials from reactive workflows to autonomous execution. By embedding intelligence directly into operations, we are unlocking faster enrollment, broader patient access, and materially better economics for biopharma. This is the infrastructure layer the industry has been waiting for—and we believe it represents a compelling growth opportunity for investors who understand the scale of this market.”
Strategic Implications for Biopharma and Investors
As clinical development costs rise and enrollment remains the leading cause of trial delays, Reticulum Nexus positions Massive Bio at the intersection of AI infrastructure, clinical operations, and precision medicine. Designed to scale across therapeutic areas and geographies, the platform enables faster trials, improved access, and long-term enterprise value creation.
Massive Bio is actively engaging venture capital firms, growth equity investors, and strategic partners during JPM Healthcare Conference week to discuss commercialization, expansion, and collaboration opportunities.
An Intelligent Operating System for Clinical Trials
At its core, Reticulum Nexus functions as a learning, self-optimizing operating system, coordinating an ecosystem of more than 100 specialized AI agents. These agents manage critical workflows across the enrollment journey, including medical record collection, eligibility assessment, trial strategy planning, unified site coordination, and patient navigation with last-mile concierge services.
By continuously ingesting real-time clinical, genomic, and operational data, the platform adapts dynamically reducing friction, shortening cycle times, and ensuring that eligible patients are not only identified but actively guided from onboarding through enrollment and ongoing participation.
From Matching to Orchestration
Unlike traditional matching technologies that stop at identification, Reticulum Nexus embeds decision-making intelligence directly into execution. The platform autonomously coordinates next-best actions across patients, sites, and trial stakeholders, closing the gap between eligibility and enrollment and improving predictability for sponsors.
About Massive Bio:
Massive Bio, co-founded by Selin Kurnaz, Arturo Loaiza-Bonilla, and Çağatay Çulcuoğlu, transforms the pharmaceutical value chain with AI-driven solutions. As an AI-enabled real-world data company, it streamlines the patient’s journey, enhances access to advanced treatment options, and optimizes clinical trials. Massive Bio collaborates with pharmaceutical companies, research organizations, and healthcare institutions worldwide. A founding member of the CancerX public-private partnership and participant in the Cancer Moonshot White House initiative, the company has received recognition from the National Cancer Institute and operates across 17 countries with a global team of over 100 employees. For more information, visit www.massivebio.com.
Contacts
Media Contacts:
Massive Bio
Mert Turkkan
Marketing Director
[email protected]
